Evidence map›Paper›PMID 21955038›Full record

ArticleBiochemistry2011

Examining docking interactions on ERK2 with modular peptide substrates.

Sunbae Lee, Mangalika Warthaka, Chunli Yan, Tamer S Kaoud, Pengyu Ren, Kevin N Dalby

Abstract read
In one paragraph

Article in Biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Bipartite binding of the intrinsically disordered scaffold protein JIP1 to the kinase JNK1.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. The optimal docking strength for reversibly tethered kinases.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  5. Article
  6. Article
  7. Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway.International journal of molecular sciences · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Mapping the binding interface of ERK and transcriptional repressor Capicua using photocrosslinking.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Differential sensing of MAP kinases using SOX-peptides.Angewandte Chemie (International ed. in English) · 2014
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sunbae LeeDivision of Medicinal Chemistry, University of Texas at Austin, Texas 78712, United States.
Mangalika Warthaka
Chunli Yan
Tamer S Kaoud
Pengyu Ren
Kevin N Dalby
The University of Texas at Austin · US

Funding

Mechanism and Specificity of MAP KinasesR01GM059802 · NIGMS · UNIVERSITY OF TEXAS AUSTIN · PI DALBY, KEVIN N · 2001 to 2011
$2.3M
Computational Drug Discovery with Polarizable Potential Eneergy FunctionR01GM079686 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI REN, PENGYU · 2007 to 2011
$1.1M
NIGMS NIH HHS GM59802NIGMS NIH HHS GM79686NIGMS NIH HHS R01 GM059802NIGMS NIH HHS R01 GM079686
6 · The paper itself

Abstract

ERK2 primarily recognizes substrates through two recruitment sites, which lie outside the active site cleft of the kinase. These recruitment sites bind modular-docking sequences called docking sites and are potentially attractive sites for the development of non-ATP competitive inhibitors. The D-recruitment site (DRS) and the F-recruitment site (FRS) bind D-sites and F-sites, respectively. For example, peptides that target the FRS have been proposed to inhibit all ERK2 activity (Galanis, A., Yang, S. H., and Sharrocks, A. D. (2001) J. Biol. Chem. 276, 965-973); however, it has not been established whether this inhibition is steric or allosteric in origin. To facilitate inhibitor design and to examine potential coupling of recruitment sites to other ligand recognition sites within ERK2, energetic coupling within ERK2 was investigated using two new modular peptide substrates for ERK2. Modeling shows that one peptide (Sub-D) recognizes the DRS, while the other peptide (Sub-F) binds the FRS. A steady-state kinetic analysis reveals little evidence of thermodynamic linkage between the peptide substrate and ATP. Both peptides are phosphorylated through a random-order sequential mechanism with a k(cat)/K(m) comparable to Ets-1, a bona fide ERK2 substrate. Occupancy of the FRS with a peptide containing a modular docking sequence has no effect on the intrinsic ability of ERK2 to phosphorylate Sub-D. Occupancy of the DRS with a peptide containing a modular docking sequence has a slight effect (1.3 ± 0.1-fold increase in k(cat)) on the intrinsic ability of ERK2 to phosphorylate Sub-F. These data suggest that while docking interactions at the DRS and the FRS are energetically uncoupled, the DRS can exhibit weak communication to the active site. In addition, they suggest that peptides bound to the FRS inhibit the phosphorylation of protein substrates through a steric mechanism. The modeling and kinetic data suggest that the recruitment of ERK2 to cellular locations via its DRS may facilitate the formation of F-site selective ERK2 signaling complexes, while recruitment via the FRS will likely inhibit ERK2 through a steric mechanism of inhibition. Such recruitment may serve as an additional level of ERK2 regulation.

Indexed as

Allosteric RegulationAmino Acid SequenceCatalytic DomainHydrophobic and Hydrophilic InteractionsMitogen-Activated Protein Kinase 1Molecular Sequence DataPeptidesProtein BindingProtein TransportSubstrate SpecificityMitogen-Activated Protein Kinase 1Peptides

Identifiers

PMID21955038
PMCPMC3422614
OpenAlexW1972043331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.